Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe chronic plaque psoriasis~* Active psoriasis, despite topical therapies~Exclusion Criteria:~* Other active skin diseases or skin infections~* Prior exposure to any anti-TNF therapy~* Subject has other active skin diseases~* Multiple concomitant therapy restrictions and/or washouts (topicals, UV, other systemic PS therapies)~* Poorly controlled medical conditions~* History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease.~* History of cancer or lymphoproliferative disease~* History of active TB or listeriosis, or persistent chronic or active infections~* Known to have immune deficiency or is immunocompromised~* Clinically significant abnormal laboratory test results~* Erythrodermic psoriasis or generalized pustular psoriasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): None
- B (Type: ACTIVE_COMPARATOR): None
- C (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).